株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

軸性脊椎関節炎 (axSpA):市場分析・予測

Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024

発行 Datamonitor Healthcare 商品コード 527412
出版日 ページ情報 英文 331 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
軸性脊椎関節炎 (axSpA):市場分析・予測 Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024
出版日: 2017年04月23日 ページ情報: 英文 331 Pages
概要

当レポートでは、軸性脊椎関節炎 (axSpA) の上市済み薬剤およびパイプラインの動向を調査し、疾患の概要、現在の治療オプション、治療の課題とアンメットニーズ、主な薬剤の売上の推移と予測、上市済み薬剤のプロファイル、開発パイプラインの動向などをまとめています。

axSpA市場の予測

  • エグゼクティブサマリー
  • 市場概要・市場動向
  • 市場の定義・調査手法
  • Cimzia (セルトリズマブペゴル)
  • Cosentyx (セクキヌマブ)
  • Enbrel (エタネルセプト)
  • Humira (アダリムマブ)
  • Remicade (インフリキシマブ)
  • Simponi (ゴリムマブ)
  • Stelara (ウステキヌマブ)
  • Taltz (イキセキズマブ)
  • 主要調査手法

axSpAの治療:米国・日本・EU5カ国

  • エグゼクティブサマリー
  • 主要調査手法
  • 疾患の定義・診断
  • 現在の治療オプション
  • 処方動向
  • コンプライアンス
  • 治療の課題とアンメットニーズ
  • パイプライン薬剤の影響
  • バイオシミラーの影響

axSpAの疫学:米国・日本・EU5カ国

  • エグゼクティブサマリー
  • 疾患の背景
  • 情報源・調査手法
  • 予測:強直性脊椎炎
  • 予測:レントゲン所?のない軸性脊椎関節炎
  • 予測:軸性脊椎関節炎
  • 疫学者の考察
  • 強み・制約

上市済み薬剤

  • エグゼクティブサマリー
  • 製品概要
  • キーオピニオンリーダーの調査
  • 製品プロファイル:Cimzia
  • 製品プロファイル:Cosentyx
  • 製品プロファイル:Enbrel
  • 製品プロファイル:Humira
  • 製品プロファイル:Remicade
  • 製品プロファイル:Simponi

パイプライン

  • エグゼクティブサマリー
  • 臨床パイプラインの概要
  • キーオピニオンリーダーの調査
  • 製品プロファイル (開発後期):Otezla
  • 製品プロファイル (開発後期):Stelara
  • 製品プロファイル (開発後期):Taltz
目次
Product Code: DMKC5354

Introduction

Axial spondyloarthritis (axSpA) is a chronic, systemic, inflammatory rheumatic disease that predominantly affects the spine and sacroiliac (SI) joints, leading to chronic back pain. The chronic inflammation can eventually result in new bone formation in the SI joints and spine, causing permanent impairment in spinal mobility. Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) are the two sub-diseases that comprise axSpA, the former of which is defined by radiographic evidence of inflammatory damage to the SI joints (radiographic sacroiliitis), whereas the latter is defined by findings of sacroiliitis on magnetic resonance imaging scans but without the detection of advanced sacroiliitis by conventional radiography.

Although the etiology of axSpA remains unclear, the condition is inheritable and genetics play a major role, with mutations in certain genes, including the human leukocyte antigen B27 gene, known to be associated with an increased risk of developing AS. The initial signs and symptoms of the disease, including spinal pain and stiffness, are not specific to axSpA, therefore there is often a lag time between onset and diagnosis. Studies suggest that axSpA is most prevalent in Caucasian populations and AS is typically more common in male adults, whereas nr-axSpA occurs more frequently in females. Furthermore, axSpA is often associated with a series of extra-articular manifestations and co-morbidities, including uveitis, cardiovascular risk, and inflammatory bowel disease. As a result, direct medical spending on the diagnosis and treatment of these conditions intensifies axSpA's economic impact.

TABLE OF CONTENTS

FORECAST: AXIAL SPONDYLOARTHRITIS

  • Executive Summary
  • Market Overview and Trends
  • Market Definition and Methodology
  • Cimzia (certolizumab)
  • Cosentyx (secukinumab)
  • Enbrel (etanercept)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Simponi (golimumab)
  • Stelara (ustekinumab)
  • Taltz (ixekizumab)
  • Primary Research Methodology

TREATMENT: AXIAL SPONDYLOARTHRITIS

  • Executive Summary
  • Primary Research Methodology
  • Disease Definition and Diagnosis
  • Current Treatment Options
  • Prescribing Trends
  • Compliance
  • Treatment Challenges and Unmet Needs
  • Impact of Pipeline Agents
  • Impact of Biosimilars

EPIDEMIOLOGY: AXIAL SPONDYLOARTHRITIS IN THE US, JAPAN, AND 5EU

  • Executive Summary
  • Disease Background
  • Sources and Methodology
  • Forecast: Ankylosing Spondylitis
  • Forecast: Non-Radiographic Axial Spondyloarthritis
  • Forecast: Axial Spondyloarthritis
  • Epidemiologist Insight
  • Strengths and Limitations
  • Appendix: Additional Sources

MARKETED DRUGS: AXIAL SPONDYLOARTHRITIS

  • Executive Summary
  • Product Overview
  • Key Opinion Leader Research
  • Product profile: Cimzia
  • Product profile: Cosentyx
  • Product profile: Enbrel
  • Product profile: Humira
  • Product profile: Remicade
  • Product profile: Simponi

PIPELINE: AXIAL SPONDYLOARTHRITIS

  • Executive Summary
  • Clinical Pipeline Overview
  • Key Opinion Leader Research
  • Product profile (late stage): Otezla
  • Product profile (late stage): Stelara
  • Product profile (late stage): Taltz

LIST OF FIGURES

  • Figure 1: Total axial spondyloarthritis sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Total axial spondyloarthritis sales in the US, 2016-25
  • Figure 3: Total axial spondyloarthritis sales across the five major EU markets, 2016-25
  • Figure 4: Total axial spondyloarthritis sales across Japan, 2016-25
  • Figure 5: Total axial spondyloarthritis sales according to drug class, 2016-25
  • Figure 6: Sales of Enbrel and Humira versus other established biologics within axial spondyloarthritis in the US, Japan, and five major EU markets, 2016-25
  • Figure 7: Total axial spondyloarthritis patients across the US, Japan, and five major EU markets, by drug class, 2016-25
  • Figure 8: Total sales of Cosentyx versus Cimzia and Simponi for axial spondyloarthritis in the five major EU markets, 2016-25
  • Figure 9: Total number of patients forecast to be prescribed Cosentyx versus Cimzia and Simponi for axial spondyloarthritis in the five major EU markets, 2016-25
  • Figure 10: Datamonitor Healthcare's axial spondyloarthritis forecast methodology
  • Figure 11: Price sources and calculations, by country
  • Figure 12: Cimzia sales in axial spondyloarthritis across the US and five major EU markets, by country, 2016-25
  • Figure 13: Cosentyx sales in axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 14: Enbrel sales in axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 15: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 16: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 17: Simponi sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 18: Simponi Aria sales for axial spondyloarthritis in the US, 2016-25
  • Figure 19: Stelara sales for axial spondyloarthritis across the US and five major EU markets, by country, 2016-25
  • Figure 20: Taltz sales for axial spondyloarthritis across the US and five major EU markets, by country, 2016-25
  • Figure 21: Proportion of ankylosing spondylitis patients and non-radiographic axial spondyloarthritis patients, by country (%)
  • Figure 22: Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis
  • Figure 23: Diagnosed versus undiagnosed axial spondyloarthritis patients, by country (%)
  • Figure 24: Diagnosed axial spondyloarthritis patients treated by each type of healthcare professional, by country (%)
  • Figure 25: Type of therapy received by diagnosed axial spondyloarthritis patients, by country (%)
  • Figure 26: Treated axial spondyloarthritis patients receiving monotherapy versus combination therapy, by country (%)
  • Figure 27: Distribution of axial spondyloarthritis patients according to monotherapy/combination use, by country (%)
  • Figure 28: Top four regimens used for the treatment of first-line axial spondyloarthritis patients, by country (%)
  • Figure 29: Top four biologic disease-modifying antirheumatic drugs used for the treatment of first-line axial spondyloarthritis patients, by country (%)
  • Figure 30: Total combined biologic disease-modifying antirheumatic drug use for the treatment of axSpA patients at each line of therapy, by country (%)
  • Figure 31: Total combined use of Remicade across all lines of therapy for the treatment of axial spondyloarthritis, by country (%), 2014 and 2016
  • Figure 32: Top four biologic DMARDs prescribed in Japan for the treatment of axial spondyloarthritis patients after traditional DMARDs, by line of therapy (%)
  • Figure 33: Top five biologic disease-modifying antirheumatic drugs used for the treatment of second-line axial spondyloarthritis patients, by country (%)
  • Figure 34: All prescribed biologic DMARDs used for the treatment of third-line axial spondyloarthritis patients after traditional DMARDs, by country (%)
  • Figure 35: All prescribed biologic DMARDs used for the treatment of fourth-line and later axial spondyloarthritis patients, by country (%)
  • Figure 36: Compliance rate for axial spondyloarthritis treatment, by formulation type and country (%)
  • Figure 37: Top three treatment challenges in axial spondyloarthritis
  • Figure 38: Expected market shares of DMARD-treated axial spondyloarthritis patients for currently approved and pipeline agents five years after launch, by country (%)
  • Figure 39: Physician confidence in prescribing biosimilars for axial spondyloarthritis approved on the basis of indication extrapolation, by country (%)
  • Figure 40: Summary of future usage of biosimilars at one year and three years post-launch (%)
  • Figure 41: Taxonomy of spondyloarthritis
  • Figure 42: Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis
  • Figure 43: Trends in total prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 44: Absolute growth in prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 45: Trends in diagnosed prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 46: Trends in total prevalent cases of non-radiographic axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 47: Absolute growth in prevalent cases of non-radiographic axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 48: Trends in diagnosed prevalent cases of non-radiographic axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 49: Trends in total prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 50: Absolute growth in prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 51: Trends in diagnosed prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 52: Datamonitor Healthcare's drug assessment summary for axial spondyloarthritis
  • Figure 53: Cimzia for axial spondyloarthritis - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Cimzia in axial spondyloarthritis
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Cimzia in axial spondyloarthritis
  • Figure 56: Cosentyx for axial spondyloarthritis - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary of Cosentyx in axial spondyloarthritis
  • Figure 58: Datamonitor Healthcare's drug assessment summary of Cosentyx in axial spondyloarthritis
  • Figure 59: Enbrel for axial spondyloarthritis - SWOT analysis
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Enbrel in axial spondyloarthritis
  • Figure 61: Datamonitor Healthcare's drug assessment summary of Enbrel in axial spondyloarthritis
  • Figure 62: Humira for axial spondyloarthritis - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Humira in axial spondyloarthritis
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Humira in axial spondyloarthritis
  • Figure 65: Remicade for axial spondyloarthritis - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of Remicade in axial spondyloarthritis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Remicade in axial spondyloarthritis
  • Figure 68: Simponi for axial spondyloarthritis - SWOT analysis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of Simponi in axial spondyloarthritis
  • Figure 70: Datamonitor Healthcare's drug assessment summary of Simponi in axial spondyloarthritis
  • Figure 71: Otezla for axial spondyloarthritis - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Otezla in axial spondyloarthritis
  • Figure 73: Datamonitor Healthcare's drug assessment summary of Otezla in axial spondyloarthritis
  • Figure 74: Stelara for axial spondyloarthritis - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Stelara in axial spondyloarthritis
  • Figure 76: Datamonitor Healthcare's drug assessment summary of Stelara in axial spondyloarthritis
  • Figure 77: Taltz for axial spondyloarthritis - SWOT analysis
  • Figure 78: Datamonitor Healthcare's drug assessment summary of Taltz in axial spondyloarthritis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of Taltz in axial spondyloarthritis

List of Tables

  • Table 1: Total market sales for axial spondyloarthritis in the US, Japan and five major EU markets ($m), 2016-25
  • Table 2: Total axial spondyloarthritis sales according to drug class ($m), 2016-25
  • Table 3: Total axial spondyloarthritis patients according to drug class, 2016-25
  • Table 4: Total sales of tDMARDs methotrexate and sulfasalazine across the US, Japan, and five major EU markets ($m), 2016-25
  • Table 5: Annual treatment cost per patient of Cosentyx, Cimzia, and Simponi in the US, Japan, and five major EU markets ($), 2016
  • Table 6: Total number of patients forecast to be prescribed Cosentyx versus Cimzia and Simponi for axial spondyloarthritis in the five major EU markets, 2016-25
  • Table 7: Total number of patients to be prescribed Stelara versus Taltz for axial spondyloarthritis in the US and five major EU markets, 2016-25
  • Table 8: Annual treatment cost per patient for Taltz versus Stelara for axial spondyloarthritis in the US and five major EU markets ($), 2019*
  • Table 9: Summary of brands and molecules included in Datamonitor Healthcare's patient-based axial spondyloarthritis forecast
  • Table 10: Exchange rates used for calculating prices
  • Table 11: Patent expiry dates for key marketed brands in axial spondyloarthritis in the US, Japan, and five major EU markets
  • Table 12: Forecasted launch dates of biosimilar versions of key marketed brands in axial spondyloarthritis across the US, Japan, and five major EU markets
  • Table 13: Forecast launch dates of key late-stage pipeline products in axial spondyloarthritis in the US, Japan, and five major EU markets, 2016-25
  • Table 14: Datamonitor Healthcare's price assumptions for Cimzia, by country, 2016
  • Table 15: Cimzia sales in axial spondyloarthritis across the US and five major EU markets, by country ($m), 2016-25
  • Table 16: Datamonitor Healthcare's price assumptions for Cosentyx, by country, 2016
  • Table 17: Cosentyx sales in axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 18: Datamonitor Healthcare's price assumptions for Enbrel, by country, 2016
  • Table 19: Enbrel sales in axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 20: Datamonitor Healthcare's price assumptions for Humira, by country, 2016
  • Table 21: Humira sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 22: Datamonitor Healthcare's price assumptions for Remicade, by country, 2016
  • Table 23: Remicade sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 24: Datamonitor Healthcare's price assumptions for Simponi, by country, 2016
  • Table 25: Datamonitor Healthcare's price assumptions for Simponi Aria in the US, 2018
  • Table 26: Simponi and Simponi Aria sales for axial spondyloarthritis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 27: Datamonitor Healthcare's price assumptions for Stelara, by country, 2019
  • Table 28: Stelara sales for axial spondyloarthritis across the US and five major EU markets, by country ($m), 2016-25
  • Table 29: Datamonitor Healthcare's price assumptions for Taltz, by country, 2019
  • Table 30: Taltz sales for axial spondyloarthritis across the US and five major EU markets, by country ($m), 2016-25
  • Table 31: Rheumatologists surveyed for the axial spondyloarthritis primary research study, 2016
  • Table 32: Rheumatologists surveyed for the axial spondyloarthritis primary research study, March 2016
  • Table 33: Key generic traditional disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis
  • Table 34: Key marketed biologic disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis
  • Table 35: Total combined usage of methotrexate and sulfasalazine, as monotherapies and combinations, for treatment of axSpA, by line of therapy and country (%)
  • Table 36: Total combined biologic disease-modifying antirheumatic drug use for the treatment of axSpA patients at each line of therapy, by country (%)
  • Table 37: Current usage of biosimilar infliximab, according to respondents currently prescribing the biosimilar, by country (%)
  • Table 38: Compliance rate for axial spondyloarthritis treatment, by formulation type and country (%)
  • Table 39: Relative importance of treatment challenges in axial spondyloarthritis
  • Table 40: Future usage of biosimilar infliximab, according to respondents aware of biosimilars, by country (%)
  • Table 41: Sources used for the epidemiological analysis of axial spondyloarthritis in the US, Japan, and five major EU markets
  • Table 42: Notable sources not used for the epidemiological analysis of axial spondyloarthritis in the US, Japan, and five major EU markets
  • Table 43: Total prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 44: Age-specific total prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015
  • Table 45: Gender-specific total prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015
  • Table 46: Diagnosed prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 47: Age-specific diagnosed prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015
  • Table 48: Gender-specific diagnosed prevalent cases of ankylosing spondylitis in the US, Japan, and five major EU markets, by country, 2015
  • Table 49: Prevalence of clinical features of ankylosing spondylitis in Japan, Germany, and Spain, 2015
  • Table 50: Total prevalent cases of non-radiographic axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 51: Diagnosed prevalent cases of non-radiographic axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 52: Prevalence of clinical features of non-radiographic axial spondyloarthritis in Germany, 2015
  • Table 53: Total prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 54: Diagnosed prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 55: Key marketed drugs for axial spondyloarthritis
  • Table 56: Cimzia drug profile
  • Table 57: Cimzia pivotal trial data in axial spondyloarthritis
  • Table 58: Cimzia ongoing late-phase trial in axial spondyloarthritis
  • Table 59: Cosentyx drug profile
  • Table 60: Cosentyx pivotal trial data in axial spondyloarthritis
  • Table 61: Cosentyx ongoing late-phase trials in axial spondyloarthritis
  • Table 62: Enbrel drug profile
  • Table 63: Enbrel pivotal trial data in axial spondyloarthritis
  • Table 64: Enbrel late-phase trial data in axial spondyloarthritis
  • Table 65: Humira drug profile
  • Table 66: Humira pivotal trial data in axial spondyloarthritis
  • Table 67: Humira late-phase trial data in axial spondyloarthritis
  • Table 68: Remicade drug profile
  • Table 69: Remicade pivotal trial data in axial spondyloarthritis
  • Table 70: Simponi drug profile
  • Table 71: Simponi pivotal trial data in axial spondyloarthritis
  • Table 72: Simponi Aria late-phase trial data in axial spondyloarthritis
  • Table 73: Drugs currently in late-stage development for axial spondyloarthritis
  • Table 74: Otezla drug profile
  • Table 75: Otezla Phase III data in axial spondyloarthritis
  • Table 76: Stelara drug profile
  • Table 77: Stelara Phase III trials in axial spondyloarthritis
  • Table 78: Taltz drug profile
  • Table 79: Taltz Phase III trials in axial spondyloarthritis
Back to Top